

รายการอ้างอิง

1. Hahn BH. **An overview of the pathogenesis of systemic lupus erythematosus.** In : Wallace DJ, Hahn BH, editors. Dubois' Lupus erythematosus 5th edition. Baltimore: Williams & Wilkins, 1997:69-75.
2. Lahita RG. **Clinical presentation of Systemic Lupus Erythematosus.** In : Kelly WN, Ruddy S, Harris ED, Sledge CB, editors. Textbook of Rheumatology. 5th edition. Philadelphia : WB Saunders, 1997 : 1028-39.
3. Wallace DJ, Metzger AL. **Systemic Lupus Erythematosus : Clinical aspect and treatment.** In : Koopman WJ, editor. Arthritis and Allied Conditions. A Textbook of Rheumatology. 13th edition. Baltimore : Williams and Wilkins, 1997 : 1319-45.
4. Masi AT, Kaslow RA. **Sex effects in systemic lupus erythematosus.** Arthritis and Rheumatism. 1978 May;21(4):480-484.
5. Lahita RG. **The connective tissue diseases and the overall influence of gender.** International Journal of Fertility 1996;41(2):156-65.
6. Evans WS, Carlsen E, Ho KY. **Prolactin and its disorders.** in Becker KL, editor. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott, 1990:134-40.
7. Fox RA, Moore PM, Isenberg DA. **Neuroendocrine changes in systemic lupus erythematosus and Sjögren's syndrome.** Baillière's Clinical Rheumatology 1996 May;10(2):333-47.
8. Kaslow RA, Masi AT. **Age, sex, and race effects on mortality from systemic lupus erythematosus in the United States.** Arthritis and Rheumatism 1978 May;21(4):473-9.
9. Petri M, Howard D, Repke J. **Frequency of lupus flare in pregnancy.** The Hopkins Lupus Pregnancy Center experience. Arthritis and Rheumatism. 1991;34:1538-47.
10. Frantz AG. **Prolactin.** The New England Journal of Medicine 1978;298(4):201-7.
11. Daniels GH, Martin JB. **Neuroendocrine Regulation and Diseases of the Anterior Pituitary and Hypothalamus.** In Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL, editors. Harrison's Principle of Internal Medicine. 13th edition. New York: McGraw-Hill, 1994:1891-1918.

12. Walker SE. **The importance of sex hormones in lupus.** In Wallace DJ, Hahn BH, editors. Dubois' Lupus erythematosus 5th edition. Baltimore: Williams & Wilkins, 1997:311-22.
13. McMurray RW. **Prolactin and systemic lupus erythematosus.** *Ann Med Interne* 1996;147:253-58.
14. Bryant HU, Holaday JW, Berniton EW. **Cysteamine produces dose-related bidirectional immunomodulatory effects in mice.** *The Journal of Pharmacology and Experimental Therapeutics* 1989;249:424-9.
15. Funauchi M, Sugishima H, Minoda M, Horiuchi A. **Effect of interferon- γ on B lymphocytes of patients with systemic lupus erythematosus.** *The Journal of Rheumatology* 1991;18(3):368-72.
16. Gutiérrez MA, Molina JF, Jara LJ, García C, Gutiérrez-Ureña S, Cuèllar ML, et al. **Prolactin-induced immunoglobulin and autoantibody production by peripheral blood mononuclear cells from systemic lupus erythematosus and normal individuals.** *International Archives of Allergy and Immunology* 1996;109:229-35.
17. Viselli SM, Stanek EM, Mukherjee P, Hymer WC, Mastro AM. **Prolactin-induced Mitogenesis of lymphocytes from ovariectomized rats.** *Endocrinology* 1991;129(2):983-90.
18. McMurray R, Keisler D, Kanuckel K, Izui S, Walker SE. **Prolactin influences autoimmune disease activity in the female B/W mouse.** *The Journal of Rheumatology* 1991 Dec;147(11):3780-7.
19. McMurray R, Keisler D, Izui S, Walker SE. **Hyperprolactinemia in male NZB/NZW(B/W) F₁ mice: accelerated autoimmune disease with normal circulating testosterone.** *Clinical Immunology and Immunopathology.* 1994 June;71(3):338-43.
20. Hori M, Sharp GC, Wang G, Schlechte JA, Walker SE. **High occurrence of fluorescent antinuclear antibody(FANA) tests and unique immunoblot patterns in hyperprolactinemic men[abstract].** *Arthritis and Rheumatism (Suppl)* 1995;38:S172.

21. Lavalle C, Loyo E, Paniagua R, Bermudez JA, Herrera J, Graef A, et al. **Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus.** *The Journal of Rheumatology* 1987;14:268-72.
22. Folomeev M, Prokaeva T, Nassonova V. **Prolactin level in men with SLE and RA**[letter]. *The Journal of Rheumatology* 1990;17:1569-70.
23. Sequeira JF, Keser G, Greenstein B, Wheeler MJ, Duarte PC, Khamashta, Hughes GR. **Systemic lupus erythematosus: Sex hormones in male patients.** *Lupus* 1993;2:315-7.
24. Athreya BH, Rafferty JH, Sehgal GS, Lahita RG. **Adenohypophyseal and sex hormones in pediatric rheumatic diseases.** *Journal of Rheumatology* 1993;20:725-30.
25. Jara-Quezada L, Graef A, Lavalle C. **Prolactin and gonadal Hormones during pregnancy in systemic lupus erythematosus.** *The Journal of Rheumatology* 1991;18:349-53.
26. Peuzner R, Urowitz MB, Gladman DD, Gough JM. **Prolactin in Systemic Lupus Erythematosus.** *The Journal of Rheumatology* 1994; 21:2064-7.
27. Buskila D, Lobber M, Neumann L, Flusser D, Shoenfeld Y. **No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus.** *Journal of Rheumatology* 1996;23:629-32.
28. Mok CC, Lau CS, Tam SCF. **Prolactin profile in a cohort of Chinese systemic lupus erythematosus patients.** *British Journal of Rheumatology* 1997;36:986-9.
29. Jara LJ, Gomez-Sanchez C, Silveira LH, Martinez-Osuna P, Vasey FB, Espinosa LR. **hyperprolactinemia in Systemic Lupus Erythematosus: Association with disease activity.** *The American Journal of The Medical Sciences* 1992;303(4):222-6.
30. El-garf A, Salah S, Shaarawy M, Zaki S, Anwer S. **Prolactin hormone in juvenile systemic lupus erythematosus: A possible relation to disease activity and CNS manifestations.** *Journal of Rheumatology* 1996;23:374-7.
31. McMurray RW, Allen SH, Braun AL, Rodriguez F, Walker SE. **Longstanding hyperprolactinemia association with Systemic Lupus Erythematosus: Possible hormonal stimulation of an autoimmune disease.** *The Journal of Rheumatology* 1994; 21:843-50.

32. McMurray RW, Weidensaul D, Allen SH, Walker SE. **Efficacy of bromocriptine in an open label therapeutic trial for Systemic Lupus Erythematosus.** The Journal of Rheumatology 1995; 22:2084-91.
33. Rabinovich CE, Schanberg LE, Kredich DW. **Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus**[abstract]. Arthritis and Rheumatism 1990;33:R22.
34. Conconi MV, Walker AM. **Chloroquine affects prolactin secretion and golgi morphology in the mammothroph.** Endocrinology 1984;114(3):725-34.
35. Ogawa N, Miyoshi M, Takahara J, Ofuji T. **Inhibitory effects of glucocorticoids on prolactin release induced by thyrotropin-releasing hormone in man.** Acta Med Okayama 1975;29:351-4.
36. Chen CL, Meites J. **Effects of estrogen and progesterone on serum and pituitary prolactin levels in ovariectomized rats.** Endocrinology 1970;86:503-5.
37. Batrinos ML, Panitsa-Fafli C, Tsiganou E, Liapi C. **Incidence and characteristics of microprolactinoma(3-5 mm) in 4199 women assayed for prolactin.** Hormone and Metabolic Research. 1992 Aug;24(8):384-91.
38. Miyai K, Ichihara K, Kondo K, Mori S. **Asymptomatic hyperprolactinemia and prolactinoma in the general population mass screening by paired assays of serum prolactin.** Clinical Endocrinology 1986;25:549-54.
39. McNeilly AS, Chard T. **Circulating level of prolactin during the menstrual cycle.** Clinical Endocrinology 1974;3:105-12.
40. Ehara Y, Silver T, VandenBerg G, Sinha YN, Yen SSC. **Circulating prolactin levels during the menstrual cycle: Episodic release and diurnal variation.** American Journal of Obstetric and Gynecology 1973 Dec;117(7):962-70.
41. Tennekoon KH, Lenton EA. **Synchronous secretion of LH and prolactin during the normal menstrual cycle.** Asia-Oceania Journal of Obstetric and Gynecology 1993;19 (1): 101-7.

42. Franchimont P, Dourcy C, Legros JJ, Reuter A, Vrindtd-Gevaert Y, Van CauwenBerge, et al. **Prolactin level during the menstrual cycle.** *Clinical Endocrinology* 1976;5:643-50.
43. Vakemans M, Delvoye P, L'Hermite M, Robyn. **Serum prolactin during the menstrual cycle.** *Journal of Clinical Endocrinology and Metabolism* 1977;44:989-93.
44. Sassin Jf, Frantz AG, Kapen S, Weitzman ED. **The nocturnal rise of human prolactin is dependent on sleep.** *Journal of Clinical Endocrinology and Metabolism* 1973;37:436-40.
45. Fujimoto VY, Clifton DK, Cohen NL, Soules MR. **Variability of serum prolactin and progesterone level in normal women : the relevance of single hormone measurements in the clinical setting.** *Obstetric and Gynecology* 1990 July;76(1):71-8.
46. Koenig KL, Toniolo P, Bruning PF, Bonfrer JM, Shore RF, Pasternack BS. **Reliability of serum prolactin measurements in women.** *Cancer Epidemiology, Biomarkers & Prevention.* 1993 Sep-Oct;2(5): 411-4.
47. Jeffcoate SL. **Diagnosis of hyperprolactinemia.** *The Lancet* 1978 Dec;9:1245-7.
48. Armeanu MC, Frölich M, Lequin RM. **Circadian rhythm of prolactin during the menstrual cycle.** *Fertility and Sterility* 1986 Aug;46(2):315-6.
49. Carr BR. **Disorders of the ovary and female reproductive tract.** In Wilson JD, Foster DW, editors. *Williams Textbook of Endocrinology.* Philadelphia : W.B. Saunders,1992:733-98.
50. Barbieri RL, Ryan KJ. **The menstrual cycle.** In Ryan KJ, Berkowitz RS, Barbieri RL, editors. *Kistner's Gynecology : Principles and Practice* 6th edition. St. Louis : Mosby,1990:11-49.
51. Buyon JP, Wallace DJ. **The endocrine system, use of exogenous estrogens, and the urogenital tract.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus* 5th edition. Baltimore: Williams & Wilkins, 1997:817-834.
52. Lim GS, Petri M, Goldman D. **Menstruation and systemic lupus erythematosus: a case-control study[abstract].** *Arthritis and Rheumatism* 1993;36:R23.

53. Liang MH, Socher SA, Larson MG, Schur PH. **Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus.** *Arthritis and Rheumatism* 1989;32(9):1107-18.
54. Kalunian KC. **Definition, classification, activity and damage indices.** In :Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:19-29.
55. Tan EM, Cohen AS, Fries JF, Masi AT, NeShane DJ, Rothfield NF, et al. **The 1982 revised criteria for the classification of systemic lupus erythematosus.** *Arthritis and Rheumatism* 1982;25(11):1271-7.
56. ทัสสนี นุชประยูร. การวิจัยเชิงวิเคราะห์และการใช้สถิติ. ใน ทัสสนี นุชประยูร, เต็มศรี ชำนิ จารกิจ บรรณาธิการ. สถิติในการวิจัยทางการแพทย์. 2537:152-219..
57. Hochberg MC. **The epidemiology of Systemic lupus erythematosus.** In :Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:49-65.
58. Kitridou RC. **The fetus in Systemic Lupus Erythematosus.** In :Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:1003-21.
59. Wallace DJ. **The clinical presentation of Systemic lupus erythematosus.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:627-33.
60. Sontheimer RD, Provost TT. **Cutaneous manifestations of Lupus erythematosus.** In :Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:569-623.
61. Wallace DJ. **The musculoskeletal system.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:635-51.
62. Wallace DJ, HahnBH, Klippel JH. **Lupus nephritis.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:1053-65.

63. Wallace DJ, Metzger AL. **Systemic lupus erythematosus and the nervous system.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:723-54.
64. Quismorio FP. **Hematologic and Lymphoid abnormalities in Systemic lupus erythematosus.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:793-816.
65. Reichlin M, Harley JB. **Antinuclear antibodies: an overveiw.** In : Wallace DJ, Hahn BH, editors. *Dubois' Lupus erythematosus 5th edition.* Baltimore: Williams & Wilkins, 1997:397-405.
66. Boumpas DT, Austin III HA, Vaughan EM, Yarboro CH, Klippel JH, Ballow JE. **Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy.** *Annals of Internal Medicine* 1993;119 (5):366-9.
67. Mukherjee P, Mastro AM, Hymer WC. **Prolactin receptors induction of IL-2 receptors on rat splenic lymphocytes.** *Endocrinology* 1990;126:88-94.
68. Russell DH, Kibler R, Matrisain L, Larson DF, Poulos B, Magun BE. **Prolactin receptors on human T and B lymphocytes: Antagonism of prolactin binding by cyclosporin.** *The Journal of Immunology* 1985;134(5):3027-31.
69. Munoz JA, Gil A, Lopez-Dupla JM, Vazquez JJ, Gonzalez-Gancedo P. **Sex hormone in chronic systemic lupus erythematosus.** *Ann. Med. Interne.* 1994;145(7):459-63.
70. Lindstedt G. **Endogeneous antibodies against prolactin—a “new” cause of hyperprolactinemia.** *European Journal of Endocrinology* 1994;130:429-32.
71. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi. **Effects of anti-prolactin autoantibodies on serum prolactin measurements.** *European Journal of Endocrinology* 1994;130:434-7.
72. Hattori N, Ikekubo K, Ishihara T, Moridera K, Hino M, Kurahachi. **Correlation of antibody titer s with serum prolactin levels and their clinical course in patients with anti-prolactin antibody.** *European Journal of Endocrinology* 1994;130:438-45.

ภาคผนวก 1

แบบใบรวบรวมข้อมูลสำหรับการศึกษารื่อง Prolactin สำหรับ Case SLE

วันที่ _____ Study ID _____

ชื่อ-สกุล _____

HN _____ SLE number _____

Birth date _____ Age _____ ปี

Weigth _____ Kg. Height _____ cm.

Duration of disease _____ Rt. Lt. Predominate

ประวัติทาง OB-GYN G ___ P ___ A ___ Last _____ Mens I ___ D ___

LMP _____ PMP _____

Criteria of SLE 1. _____ 2. _____

3. _____ 4. _____

5. _____ 6. _____

Exclusion criteria Y N a. hormonal con. b. pregnancy, lactation c. neurologic dis.

Organs of involvement

1. muco-cutaneous (in 3 months) Y N

a. malar rash b. SCLE c. DLE d. oral ulceration

2. arthritis (in 3 months) Y N

3. lupus nephritis (in 1 year) Y N

a. nephritis 1.RBC >5 or cellular cast and 2.proteinuria >0.5 g/d or >3+

b. nephrotic syndrome (proteinuria > 3.5 g/d)

c. kidney pathology type _____

4. neuropsychritic lupus (in 1 year) Y N

a. seizure b. psychosis

Current drug used _____

SLAM score = _____

ภาคผนวก 2

แบบตรวจสอบคุณสมบัติของกลุ่มควบคุม

ชื่อ-สกุล _____ HN _____
วันเกิด _____ อายุ _____ ปี กลุ่มควบคุมเลขที่ _____
ที่ทำงาน _____ โทร _____
น้ำหนัก _____ กก. ส่วนสูง _____ ซม.
ตั้งครรภ์ _____ หน คลอด _____ หน แท้ง _____ หน
LMP _____ มา _____ วัน PMP _____ มา _____ วัน
ถนัด ซ้าย ขวา

- 1) เป็นสตรีที่ยังมีประจำเดือนค่อนข้างสม่ำเสมอ (แต่ละรอบเดือนไม่สั้นกว่า 24 วัน และไม่ห่างเกิน 35 วัน) ในช่วง 2 เดือน ที่ผ่านมา ใช่
- 2) ไม่มีโรคประจำตัว โดยเฉพาะโรคของระบบประสาท และไม่มีอาการที่สงสัยจะเป็นโรค SLE เช่น ปวดข้อ มีผื่นที่หน้า แพ้แดด บวม ใช่
- 3) ไม่ได้ใช้ยาต่อไปนี้อยู่
 - ก. ยา Antipsychotic (ยาโรคจิต)
 - ข. Metoclopramine (Plasil)
 - ค. Cimetidine (Tagamet) (ยาโรคกระเพาะอาหาร)
 - ง. Opiates (ยาเข้าฝิ่น)
 - จ. Methyldopa (ยาลดความดัน)
 - ฉ. ยาคุมกำเนิดทั้งแบบฉีดและกิน ใช่
- 4) ไม่ได้ตั้งครรภ์หรือให้นมบุตร ใช่
- 5) งดอาหารแห้งที่ยังกิน(ทานเฉพาะน้ำเปล่า) และเริ่มมีประจำเดือนวันแรก(หรือไม่เกิน 4 วัน) แล้ว และมาที่ปร.3 ระหว่างเวลา 8.00-12.00 น. ใช่
- 6) แพทย์สัมภาษณ์และตรวจร่างกายแล้วเข้าสู่การศึกษาได้ ใช่

มีคุณสมบัติต่อไปนี้ครบถ้วน ใช่ ไม่ใช่

ภาคผนวก 3

The Systemic Lupus Erythematosus Activity Measure (SLAM)

SLE ACTIVITY MEASURE
(OVER LAST MONTH)

NAME
DATE
RATER

CONSTITUTIONAL		ABSENT or NORMAL	MILD - MODERATE	SEVERE	NOT RECORDED	
1. Weight loss	<input type="checkbox"/> 0	<input type="checkbox"/> 1 <10% body weight	<input type="checkbox"/> 3 >10%	<input type="checkbox"/>		
2. Fatigue	<input type="checkbox"/> 0	<input type="checkbox"/> 1 No limits on activity	<input type="checkbox"/> 3 Functional limitation	<input type="checkbox"/>		
3. Fever	<input type="checkbox"/> 0	<input type="checkbox"/> 1 37.5-38.5°C	<input type="checkbox"/> 3 >38.5°C	<input type="checkbox"/>		
INTEGUMENT		ABSENT or NORMAL	MILD	MODERATE	SEVERE	NOT RECORDED
4. Oral/nasal ulcers, or periungual erythema, or malar rash, or photosensitive rash or nail fold infarct	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Present			<input type="checkbox"/>	
5. Alopecia	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Hair loss with trauma	<input type="checkbox"/> 2 Spontaneous hair loss		<input type="checkbox"/>	
6. Erythematous, maculopapular rash, or discoid lupus, or lupus profundus, or bullous lesions	<input type="checkbox"/> 0	<input type="checkbox"/> 1 <20% Total Body Surface (TBA)	<input type="checkbox"/> 2 20-50% TBA	<input type="checkbox"/> 3 >50% TBA	<input type="checkbox"/>	
7. Vasculitis (leucocytoclastic vasculitis, urticaria, palpable purpura, livedo reticularis, ulcer or panniculitis)	<input type="checkbox"/> 0	<input type="checkbox"/> 1 <20% TBA	<input type="checkbox"/> 2 20-50% TBA	<input type="checkbox"/> 3 >50% TBA or necrosis	<input type="checkbox"/>	
EYE		ABSENT or NORMAL	MILD	MODERATE	SEVERE	NOT RECORDED
8. Cytoid bodies	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Present			<input type="checkbox"/> 3 visual acuity < 20/200	<input type="checkbox"/>
9. Hemorrhages (retinal or choroidal) or episcleritis	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Present			<input type="checkbox"/> 3 visual acuity < 20/200	<input type="checkbox"/>
10. Papillitis or pseudotumor cerebri	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Present			<input type="checkbox"/> 3 visual acuity < 20/200 or field cut	<input type="checkbox"/>
RETICULOENDOTHELIAL		ABSENT or NORMAL	MILD	MODERATE	SEVERE	NOT RECORDED
11. Diffuse lymphadenopathy (cervical, axillary, epitrochlear)	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Shotty		<input type="checkbox"/> 2 >1cm x 1.5cm		<input type="checkbox"/>
12. Hepato- or splenomegaly	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Palpable only with inspiration		<input type="checkbox"/> 2 Palpable without inspiration		<input type="checkbox"/>

PULMONARY

	ABSENT or NORMAL	MILD	MODERATE	SEVERE	NOT RECORDED
13. Pleural effusion/pleurisy	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Shortness of breath or pain only with prompting. Exam normal or near normal.	<input type="checkbox"/> 2 Shortness of breath or pain with exercise, decreased breath sounds and dull lower lobe(s).	<input type="checkbox"/> 3 Shortness of breath or pain at rest, decreased breath sounds and dull middle and lower lobes.	<input type="checkbox"/>
14. Pneumonitis	<input type="checkbox"/> 0	<input type="checkbox"/> 1 X-ray infiltrates only	<input type="checkbox"/> 2 Shortness of breath with exercise	<input type="checkbox"/> 3 Shortness of breath at rest	<input type="checkbox"/>

CARDIOVASCULAR

15. Raynaud's	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Present			<input type="checkbox"/>
16. Hypertension	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Diast. 90-105	<input type="checkbox"/> 2 Diast. 105-115	<input type="checkbox"/> 3 Diast. >115	<input type="checkbox"/>
17. Carditis	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Pericarditis by EKG &/or RUB &/or effusion by echo; no sx	<input type="checkbox"/> 2 Chest pain or arrhythmia	<input type="checkbox"/> 3 Myocarditis with hemodynamic compromise &/or arrhythmia	<input type="checkbox"/>

GASTROINTESTINAL

18. Abdominal pain (Serositis, pancreatitis, ischemic bowel, etc.)	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Complaint	<input type="checkbox"/> 2 Limiting Pain	<input type="checkbox"/> 3 Peritoneal signs/ascites	<input type="checkbox"/>
-----------------------------------------------------------------------	----------------------------	-----------------------------------------	---------------------------------------------	--------------------------------------------------------	--------------------------

NEUROMOTOR

19. Stroke syndrome (includes mononeuritis multiplex, transient ischemic attack(TIA), reversible ischemic neurologic deficit (RIND), cerebrovascular accident (CVA), retinal vascular thrombosis)	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Single TIA	<input type="checkbox"/> 2 Multiple TIA/RIND, or mononeuritis multiplex or cranial neuropathy or chorea	<input type="checkbox"/> 3 CVA/myelitis, retinal vascular occlusion	<input type="checkbox"/>
20. Seizure	<input type="checkbox"/> 0	<input type="checkbox"/> 1 1-2/month	<input type="checkbox"/> 2 > 2/month	<input type="checkbox"/> 3 Status epilepticus	<input type="checkbox"/>
21. Cortical dysfunction	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Mild depression/ personality disorder or cognitive deficit	<input type="checkbox"/> 2 Δ in sensorium or severe depression or limiting cognitive impairment	<input type="checkbox"/> 3 Psychosis or dementia or coma	<input type="checkbox"/>
22. Headache (including migraine equivalents)	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Symptoms or transient neuro deficit	<input type="checkbox"/> 2 Interferes somewhat with normal activities	<input type="checkbox"/> 3 Incapacitating/ aseptic meningitis	<input type="checkbox"/>
23. Myalgia/myositis	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Complaint	<input type="checkbox"/> 2 Limits some activity	<input type="checkbox"/> 3 Incapacitating	<input type="checkbox"/>

JOINTS

	ABSENT or NORMAL	MILD	MODERATE	SEVERE	NOT RECORDED
24. Joint pain from synovitis and/or tenosynovitis	<input type="checkbox"/> 0	<input type="checkbox"/> 1 Arthralgia only	<input type="checkbox"/> 2 Objective inflammation	<input type="checkbox"/> 3 Limited function	<input type="checkbox"/>

OTHER

25. (Write rules for ascertainment and ad hoc scale)	<input type="checkbox"/> 0	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
------------------------------------------------------	----------------------------	--------------------------	--------------------------	--------------------------	--------------------------


LABORATORY

	NORMAL	MILD	MODERATE	SEVERE	UNKNOWN, NOT RECORDED
26. Hematocrit	<input type="checkbox"/> 0 >35	<input type="checkbox"/> 1 30-35	<input type="checkbox"/> 2 25-29.9	<input type="checkbox"/> 3 <25	<input type="checkbox"/>
27. WBC	<input type="checkbox"/> 0 >3500	<input type="checkbox"/> 1 3500-2000	<input type="checkbox"/> 2 2000-1000	<input type="checkbox"/> 3 <1000	<input type="checkbox"/>
28. Lymphocyte count	<input type="checkbox"/> 0 1500-4000	<input type="checkbox"/> 1 1499-1000	<input type="checkbox"/> 2 999-500	<input type="checkbox"/> 3 <499	<input type="checkbox"/>
29. Platelet count	<input type="checkbox"/> 0 >150T	<input type="checkbox"/> 1 100-150T	<input type="checkbox"/> 2 99-50T	<input type="checkbox"/> 3 <50T	<input type="checkbox"/>
30. ESR (Westergren)	<input type="checkbox"/> 0 <25	<input type="checkbox"/> 1 25-50	<input type="checkbox"/> 2 51-75	<input type="checkbox"/> 3 >75	<input type="checkbox"/>
31. Serum creatinine or creatinine clearance	<input type="checkbox"/> 0 0.5-1.3mg/dl or 80-100%CrCl	<input type="checkbox"/> 1 1.4-2mg/dl or 79-60%CrCl	<input type="checkbox"/> 2 2.1-4mg/dl or 30-60%CrCl	<input type="checkbox"/> 3 >4mg/dl or <30%CrCl	<input type="checkbox"/>
32. Urine sediment	<input type="checkbox"/> 0	<input type="checkbox"/> 1 >5 RBC &/or WBC/hpf &/or 0 to 1-3 granular &/or cellular casts/hpf &/or 1-2+ proteinuria &/or <500 mg/L 24 ^h urine protein	<input type="checkbox"/> 2 > 10 RBC &/or WBC/hpf or >3 granular &/or cellular casts/hpf &/or 3 or 4+ &/or 500 mg/L-3.5 g/L 24 ^h urine protein	<input type="checkbox"/> 3 >25 RBC or WBC/hpf &/or Red cell cast &/or >4+ proteinuria &/or >3.5 g/L 24 ^h urine protein	<input type="checkbox"/>

MD GLOBAL RATING OF SLE ACTIVITY *



PATIENT GLOBAL RATING OF THEIR DISEASE ACTIVITY



* Over last month. Use most active rating during the month.

Assume that "NONE" and "MOST ACTIVE" refer to what patient has experienced.

ประวัติผู้ทำวิทยานิพนธ์



- ชื่อ นายแพทย์บุญเอก จันศิริมงคล
- ภูมิลำเนา สงขลา
- การศึกษา แพทยศาสตรบัณฑิต เกียรตินิยมอันดับหนึ่ง
คณะแพทยศาสตร์ มหาวิทยาลัยสงขลานครินทร์
ปีการศึกษา 2535
- พ.ศ. 2535 - 2539 แพทย์ใช้ทุนภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์
มหาวิทยาลัยสงขลานครินทร์
- พ.ศ. 2539 - ปัจจุบัน แพทย์ประจำบ้านต่อยอด สาขาวิชาโรคข้อและรูมาติสซั่ม
ภาควิชาอายุรศาสตร์ จุฬาลงกรณ์มหาวิทยาลัย

สถาบันวิทย์บริการ
จุฬาลงกรณ์มหาวิทยาลัย